Provided by Tiger Trade Technology Pte. Ltd.

COMPASS Pathways plc

14.22
-0.9500-6.26%
Post-market: 14.20-0.0200-0.14%17:30 EDT
Volume:3.32M
Turnover:47.39M
Market Cap:1.96B
PE:-3.94
High:15.01
Open:14.91
Low:14.00
Close:15.17
52wk High:15.87
52wk Low:4.82
Shares:138.00M
Float Shares:107.00M
Volume Ratio:1.06
T/O Rate:3.10%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.6118
EPS(LYR):-3.0800
ROE:-319.07%
ROA:-29.08%
PB:23.21
PE(LYR):-4.62

Loading ...

Compass Pathways PLC Expected to Post a Loss of 40 Cents a Share - Earnings Preview

Reuters
·
Jul 27

Compass Pathways Initiated at Equal-Weight by Wells Fargo

Dow Jones
·
Jul 27

Wells Fargo Initiates COMPASS Pathways at Equalweight

MT Newswires Live
·
Jul 27

Compass Pathways initiated with an Equal Weight at Wells Fargo

TIPRANKS
·
Jul 27

COMPASS Pathways PLC put volume heavy and directionally bearish

TIPRANKS
·
Jul 18

European Equities Traded in the US as American Depositary Receipts Edge Lower Thursday

MT Newswires Live
·
Jul 16

Compass Pathways Reports Post-hoc Analysis Showing Comp360 Trial Support Distinct from Psychotherapy

Reuters
·
Jul 16

Should COMP360’s Durable Phase 3 Results and FDA Momentum Require Action From COMPASS Pathways (CMPS) Investors?

Simply Wall St.
·
Jul 16

Analysts Have Conflicting Sentiments on These Healthcare Companies: COMPASS Pathways (CMPS), NovoCure (NVCR) and Bristol-Myers Squibb (BMY)

TIPRANKS
·
Jul 13

Analysts Are Bullish on These Healthcare Stocks: Immunome (IMNM), COMPASS Pathways (CMPS)

TIPRANKS
·
Jul 11

Wells Fargo, BKR, SLB, HAL, CMPS Trending With Analysts

TIPRANKS
·
Jul 11

European Equities Traded in the US as American Depositary Receipts Rise Thursday

MT Newswires Live
·
Jul 09

Analysts Offer Insights on Healthcare Companies: Schrodinger (SDGR), Amphastar Pharmaceuticals (AMPH) and COMPASS Pathways (CMPS)

TIPRANKS
·
Jul 09

Compass Pathways' COMP360 Data Supports FDA Approval Potential, RBC Says

MT Newswires Live
·
Jul 08

Evercore upgrades Compass Pathways to Outperform, views approval as likely

TIPRANKS
·
Jul 08

Why COMPASS Pathways (CMPS) Is Down 8.2% After New Phase 3 Data and Rolling NDA Update

Simply Wall St.
·
Jul 08

Analyst Reaffirms Buy on CMPS, Viewing Post-Data Pullback as Entry Opportunity Ahead of 1H27 Launch

TIPRANKS
·
Jul 08

Compass Pathways announces six-month data from COMP006 trial

TIPRANKS
·
Jul 08

Compass new data validates COMP360 durability profile, says Morgan Stanley

TIPRANKS
·
Jul 08

Compass Pathways is Maintained at Buy by BTIG

Dow Jones
·
Jul 08